GlassScriptPhysician profile
Ray S Davis
NPI 1821037334
$14,486.08
in general payments reported to CMS, 2019-2025
21 companies · $824 in 2025
The $824 reported for 2025 was more than what a typical Pediatric Allergy/Immunology provider received nationally (typical 2025 total: $375).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,043 · 2020: $2,510 · 2021: $6,190 · 2022: $1,404 · 2023: $268 · 2024: $248 · 2025: $824.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,110 · Travel and Lodging: $229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,110.46 |
| Travel and Lodging | $229.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $5,979.30 | 2021-2023 | |
| Genzyme Corporation | $2,769.89 | 2019-2025 | |
| Shire North American Group INC | $1,639.80 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $1,298.61 | 2022-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $842.44 | 2019-2022 | |
| Glaxosmithkline, LLC. | $384.21 | 2019-2022 | |
| Kaleo, INC. | $275.58 | 2019-2022 | |
| Alk-Abello, INC | $194.75 | 2019-2022 | |
| Genentech USA, INC. | $178.00 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $129.61 | 2019-2022 | |
| Pfizer INC. | $129.51 | 2019-2025 | |
| Blueprint Medicines Corporation | $127.82 | 2023 | |
| Optinose US, INC. | $125.27 | 2020-2022 | |
| Csl Behring | $108.98 | 2019-2022 | |
| Circassia INC. | $95.46 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.21 | 2019-2021 | |
| Grifols USA, LLC | $45.32 | 2021-2022 | |
| Eyevance Pharmaceuticals LLC | $43.08 | 2021 | |
| Aimmune Therapeutics, INC. | $29.58 | 2022 | |
| Amgen INC. | $25.58 | 2022 | |
| Mylan Specialty L.P. | $11.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ray Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.